Gustave Roussy and One Biosciences Partner to Bring Single Cell to Clinical Practice for Precision Oncology

Gustave Roussy and One Biosciences Partner to Bring Single Cell to Clinical Practice for Precision Oncology

Gustave Roussy partners with One Biosciences, a techbio company that harnesses single cell technology and AI to develop advanced precision diagnostics. The collaboration aims to further demonstrate the feasibility and impact of integrating single nuclei transcriptomic analysis into the patient care pathway.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260519540709/en/

Gustave Roussy, Europe’s leading cancer center, is teaming up with One Biosciences to harness the cutting-edge potential of OneMapTM, the single-cell and AI-powered solution helping to enhance precision oncology solutions. By analyzing anonymized frozen samples across four cancer indications, One Biosciences will deploy OneMapTM to generate ultra-high-resolution single-cell data, unlocking the hidden functional diversity of each tumor with unparalleled precision.

Prof. Sophie Postel-Vinay, oncologist at Gustave Roussy, team leader in Inserm unit U981 at Gustave Roussy and associate professor at University College of London comments: “I have seen firsthand how single-cell analysis can uncover mechanisms of treatment resistance in retrospective studies. I am very excited about using the OneMapTM solution in a prospective setting, fully integrated into the clinical workflow, as it could represent a major step forward in selecting the most appropriate treatment for each patient. We believe that OneMapTM's game-changing advantage is clear: deciphering tumor heterogeneity at the single-cell level, pinpointing unique cell populations, and exposing their function will empower clinicians and allow to make more informed and smarter decisions in the treatment of patients with advanced cancer.”